Predictors of survival in never-smokers with non-small cell lung cancer: A large-scale, two-phase genetic study

Clinical Cancer Research

Volumn 18, Issue 21, 2012, Pages 5983-5991

  Pu, Xia ^a   Ye, Yuanqing ^a   Spitz, Margaret R ^a   Wang, Liang ^c   Gu, Jian ^a   Lippman, Scott M ^a   Hildebrandt, Michelle A T ^a   Hong, Waun Ki ^a   Minna, John D ^b   Roth, Jack A ^a   Yang, Ping ^c   Wu, Xifeng ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BMP8A GENE; BPI GENE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CD38 GENE; CD74 GENE; DUSP1 GENE; ESR1 GENE; FEMALE; FGF14 GENE; GENE; GENE INTERACTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GNA12 GENE; HUMAN; IFNA8 GENE; IL10RB GENE; IL17RA GENE; INHBA GENE; LAG3 GENE; LUNG CANCER IN NEVER SMOKER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PASSIVE SMOKING; PNEUMONIA; POPULATION RESEARCH; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SLC7A5 GENE; SURVIVAL PREDICTION; SYK GENE; VALIDATION PROCESS;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; SMOKING;

EID: 84868545166     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0774     Document Type: Article

References (43)

1. Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol 2007;25:561-70. (Pubitemid 350002964)
2. Yano T, Miura N, Takenaka T, Haro A, Okazaki H, Ohba T, et al. Neversmoking nonsmall cell lung cancer as a separate entity: clinicopathologic features and survival. Cancer 2008;113:1012-8.
3. Bryant A, Cerfolio RJ. Differences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop non-small cell lung cancer. Chest 2007;132:185-92. (Pubitemid 47068220)
4. Meguid RA, Hooker CM, Harris J, Xu L, Westra WH, Sherwood JT, et al. Long-term survival outcomes by smoking status in surgical and nonsurgical patients with non-small cell lung cancer: comparing never smokers and current smokers. Chest 2010;138:500-9.
5. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39. (Pubitemid 38637993)
6. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500. (Pubitemid 38720929)
7. Leibovici D, Grossman HB, Dinney CP, Millikan RE, Lerner S, Wang Y, et al. Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol 2005;23:5746-56.
8. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res 2006;4:221-33.
9. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
10. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7. (Pubitemid 36019639)
11. Khatami M. Inflammation, aging, and cancer: tumoricidal versus tumorigenesis of immunity: a common denominator mapping chronic diseases. Cell Biochem Biophys 2009;55:55-79.
12. Sorrentino C, Di Carlo E. Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype. Am J Respir Crit Care Med 2009;180:769-79.
13. Gocheva V, Wang HW, Gadea BB, Shree T, Hunter KE, Garfall AL, et al. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev 2010;24:241-55.
14. Zeng L, O'Connor C, Zhang J, Kaplan AM, Cohen DA. IL-10 promotes resistance to apoptosis and metastatic potential in lung tumor cell lines. Cytokine 2010;49:294-302.
15. Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 2009;27:3437-44.
16. Proctor MJ, Morrison DS, Talwar D, Balmer SM, O'Reilly DS, Foulis AK, et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer 2011;104:726-34.
17. Ishizuka M, Nagata H, Takagi K, Horie T, Kubota K. Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer. Ann Surg 2007;246:1047-51. (Pubitemid 350179198)
18. Hara M, Matsuzaki Y, Shimuzu T, Tomita M, Ayabe T, Enomoto Y, et al. Preoperative serum C-reactive protein level in non-small cell lung cancer. Anticancer Res 2007;27:3001-4. (Pubitemid 47228036)
19. O'Dowd C, McRae LA, McMillan DC, Kirk A, Milroy R. Elevated preoperative C-reactive protein predicts poor cancer specific survival in patients undergoing resection for non-small cell lung cancer. J Thorac Oncol 2010;5:988-92.
20. Minamiya Y, Miura M, Hinai Y, Saito H, Ito M, Imai K, et al. The CRP 1846T/T genotype is associated with a poor prognosis in patients with non-small cell lung cancer. Tumour Biol 2010;31:673-9.
21. Pine SR, Mechanic LE, Ambs S, Bowman ED, Chanock SJ, Loffredo C, et al. Lung cancer survival and functional polymorphisms in MBL2, an innate-immunity gene. J Natl Cancer Inst 2007;99:1401-9. (Pubitemid 351767188)
22. Yang P, Allen MS, Aubry MC, Wampfler JA, Marks RS, Edell ES, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 2005;128:452-62. (Pubitemid 40994510)
23. Li Y, Sheu CC, Ye Y, de Andrade M, Wang L, Chang SC, et al. Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol 2010;11:321-30.
24. Loza MJ, McCall CE, Li L, Isaacs WB, Xu J, Chang BL. Assembly of inflammation-related genes for pathway-focused genetic analysis. PLoS One 2007;2:e1035.
25. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D. Efficiency and power in genetic association studies. Nat Genet 2005;37:1217-23. (Pubitemid 41568704)
26. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 2003;100:9440-5. (Pubitemid 37033947)
27. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med 2002;21:1539-58.
28. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity 2004;21:467-76. (Pubitemid 39370503)
29. Zhou Y, Toh ML, Zrioual S, Miossec P. IL-17A versus IL-17F induced intracellular signal transduction pathways and modulation by IL-17RA and IL-17RC RNA interference in AGS gastric adenocarcinoma cells. Cytokine 2007;38:157-64. (Pubitemid 47248300)
30. Katoh Y, Katoh M. Comparative integromics on BMP/GDF family. Int J Mol Med 2006;17:951-5.
31. Ye L, Bokobza SM, Jiang WG. Bone morphogenetic proteins in development and progression of breast cancer and therapeutic potential (review). Int J Mol Med 2009;24:591-7.
32. Singh A, Morris RJ. The Yin and Yang of bone morphogenetic proteins in cancer. Cytokine Growth Factor Rev 2010;21:299-313.
33. Corey E, Vessella RL. Bone morphogenetic proteins and prostate cancer: evolving complexities. J Urol 2007;178:750-1. (Pubitemid 47211144)
34. Ye L, Lewis-Russell JM, Kyanaston HG, Jiang WG. Bone morphogenetic proteins and their receptor signaling in prostate cancer. Histol Histopathol 2007;22:1129-47. (Pubitemid 47470307)
35. Chen H, Cowan MJ, Hasday JD, Vogel SN, Medvedev AE. Tobacco smoking inhibits expression of proinflammatory cytokines and activation of IL-1R-associated kinase, p38, and NF-kappaB in alveolar macrophages stimulated with TLR2 and TLR4 agonists. J Immunol 2007;179:6097-106.
36. Medves S, Demoulin JB. Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies. J Cell Mol Med 2012;16:237-48.
37. Ma L, Dong S, Zhang P, Xu N, Yan H, Liu H, et al. The relationship between methylation of the Syk gene in the promoter region and the genesis of lung cancer. Clin Lab 2010;56:407-16.
38. Nagata S, Jin YF, Yoshizato K, Tomoeda M, Song M, Iizuka N, et al. CD74 is a novel prognostic factor for patients with pancreatic cancer receiving multimodal therapy. Ann Surg Oncol 2009;16:2531-8.
39. Borghese F, Clanchy FI. CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease. Expert Opin Ther Targets 2011;15:237-51.
40. Stein R, Mattes MJ, Cardillo TM, Hansen HJ, ChangCH, Burton J, et al. CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res 2007;13:5556s-63s. (Pubitemid 47510387)
41. Burton JD, Ely S, Reddy PK, Stein R, Gold DV, Cardillo TM, et al. CD74 is expressed by multiple myeloma and is a promising target for therapy. Clin Cancer Res 2004;10:6606-11. (Pubitemid 39346557)
42. Malavasi F, Deaglio S, Funaro A, Ferrero E, Horenstein AL, Ortolan E, et al. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev 2008;88:841-86.
43. Mougalian SS, O'Brien S. Adverse prognostic features in chronic lymphocytic leukemia. Oncology (Williston Park) 2011;25:692-6, 9.